News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,475 Results
Type
Article (43130)
Company Profile (300)
Press Release (686032)
Multimedia
Podcasts (100)
Webinars (17)
Section
Business (210713)
Career Advice (2098)
Deals (36687)
Drug Delivery (111)
Drug Development (83224)
Employer Resources (175)
FDA (16694)
Job Trends (15461)
News (356697)
Policy (34055)
Tag
Academia (2601)
Accelerated approval (14)
Adcomms (24)
Allergies (113)
Alliances (51581)
ALS (128)
Alzheimer's disease (1532)
Antibody-drug conjugate (ADC) (176)
Approvals (16744)
Artificial intelligence (370)
Autoimmune disease (40)
Automation (23)
Bankruptcy (372)
Best Places to Work (11769)
BIOSECURE Act (20)
Biosimilars (138)
Biotechnology (188)
Bladder cancer (111)
Brain cancer (43)
Breast cancer (412)
Cancer (3327)
Cardiovascular disease (279)
Career advice (1766)
Career pathing (33)
CAR-T (205)
CDC (38)
Cell therapy (551)
Cervical cancer (27)
Clinical research (68993)
Collaboration (1206)
Company closure (4)
Compensation (840)
Complete response letters (42)
COVID-19 (2732)
CRISPR (72)
C-suite (479)
Cystic fibrosis (124)
Data (3666)
Decentralized trials (2)
Denatured (32)
Depression (81)
Diabetes (386)
Diagnostics (6570)
Digital health (27)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (166)
Drug pricing (152)
Drug shortages (31)
Duchenne muscular dystrophy (172)
Earnings (90247)
Editorial (45)
Employer branding (21)
Employer resources (151)
Events (117504)
Executive appointments (909)
FDA (18843)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1051)
Gene editing (153)
Generative AI (26)
Gene therapy (442)
GLP-1 (876)
Government (4703)
Grass and pollen (6)
Guidances (331)
Healthcare (19036)
HIV (42)
Huntington's disease (32)
IgA nephropathy (49)
Immunology and inflammation (193)
Immuno-oncology (13)
Indications (46)
Infectious disease (2925)
Inflammatory bowel disease (166)
Inflation Reduction Act (10)
Influenza (77)
Intellectual property (157)
Interviews (324)
IPO (16882)
IRA (55)
Job creations (4066)
Job search strategy (1494)
Kidney cancer (13)
Labor market (63)
Layoffs (546)
Leadership (23)
Legal (8407)
Liver cancer (84)
Longevity (12)
Lung cancer (480)
Lymphoma (245)
Machine learning (21)
Management (59)
Manufacturing (515)
MASH (110)
Medical device (13641)
Medtech (13658)
Mergers & acquisitions (20606)
Metabolic disorders (963)
Multiple sclerosis (110)
NASH (17)
Neurodegenerative disease (156)
Neuropsychiatric disorders (39)
Neuroscience (2356)
NextGen: Class of 2025 (6642)
Non-profit (4540)
Now hiring (53)
Obesity (477)
Opinion (254)
Ovarian cancer (111)
Pain (150)
Pancreatic cancer (142)
Parkinson's disease (200)
Partnered (24)
Patents (367)
Patient recruitment (260)
Peanut (54)
People (59996)
Pharmaceutical (90)
Pharmacy benefit managers (23)
Phase I (21375)
Phase II (30360)
Phase III (22725)
Pipeline (2389)
Policy (243)
Postmarket research (2655)
Preclinical (9126)
Press Release (68)
Prostate cancer (161)
Psychedelics (41)
Radiopharmaceuticals (261)
Rare diseases (542)
Real estate (6277)
Recruiting (68)
Regulatory (23974)
Reports (51)
Research institute (2382)
Resumes & cover letters (359)
Rett syndrome (11)
RNA editing (12)
RSV (55)
Schizophrenia (114)
Series A (173)
Series B (130)
Service/supplier (12)
Sickle cell disease (71)
Special edition (21)
Spinal muscular atrophy (151)
Sponsored (35)
Startups (3747)
State (2)
Stomach cancer (15)
Supply chain (87)
Tariffs (80)
The Weekly (66)
Vaccines (888)
Venture capital (59)
Weight loss (306)
Women's health (51)
Worklife (17)
Date
Today (111)
Last 7 days (428)
Last 30 days (2221)
Last 365 days (31372)
2025 (21813)
2024 (35769)
2023 (40630)
2022 (51799)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33137)
2016 (32662)
2015 (38616)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (788)
Alabama (69)
Alaska (7)
Arizona (265)
Arkansas (14)
Asia (41352)
Australia (6607)
California (8550)
Canada (2647)
China (794)
Colorado (357)
Connecticut (364)
Delaware (226)
Europe (88506)
Florida (1276)
Georgia (285)
Hawaii (2)
Idaho (60)
Illinois (695)
India (40)
Indiana (408)
Iowa (17)
Japan (264)
Kansas (114)
Kentucky (31)
Louisiana (16)
Maine (65)
Maryland (1139)
Massachusetts (6305)
Michigan (266)
Minnesota (507)
Mississippi (4)
Missouri (101)
Montana (28)
Nebraska (25)
Nevada (98)
New Hampshire (68)
New Jersey (2343)
New Mexico (29)
New York (2325)
North Carolina (1210)
North Dakota (8)
Northern California (3866)
Ohio (261)
Oklahoma (17)
Oregon (40)
Pennsylvania (1811)
Puerto Rico (17)
Rhode Island (41)
South America (1165)
South Carolina (44)
South Dakota (1)
Southern California (3281)
Tennessee (138)
Texas (1320)
United States (31268)
Utah (254)
Virginia (221)
Washington D.C. (74)
Washington State (712)
West Virginia (4)
Wisconsin (74)
729,475 Results for "agios pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
Report of Patient Deaths Sends Agios Shares Seesawing
While the deaths occurred in patients who had been treated with Agios’ anemia treatment Pyrukynd, the biotech insisted in an SEC filing midday Monday that the drug’s risk-benefit profile remains unchanged.
August 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
September 4, 2025
·
9 min read
Press Releases
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
August 5, 2025
·
9 min read
Press Releases
Agios Appoints Dr. Jay Backstrom to Board of Directors
July 9, 2025
·
5 min read
Press Releases
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
July 31, 2025
·
10 min read
Press Releases
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
July 15, 2025
·
1 min read
Press Releases
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders
June 9, 2025
·
2 min read
Press Releases
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
May 28, 2025
·
1 min read
Press Releases
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
May 2, 2025
·
1 min read
Press Releases
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
May 9, 2025
·
1 min read
1 of 72,948
Next
